Low eligibility for hepatitis B treatment in the Brazilian public health system

被引:1
|
作者
Oliveira Scarponi, Cristiane Faria [1 ]
Ferreira Pedrosa, Marco Antonio [2 ]
Gomes Mol, Marcos Paulo [3 ]
Mascarenhas Hardman, Michael John [4 ]
Greco, Dirceu Bartolomeu [5 ]
机构
[1] Fundacao Ezequiel Dias, Div Epidemiol & Controle Doencas, Belo Horizonte, MG, Brazil
[2] GeOpem Engn & Tecnol Ltd, Brejo Santo, CE, Brazil
[3] Fundacao Ezequiel Dias, Div Ciencia & Inovacao, Belo Horizonte, MG, Brazil
[4] Frimley Hlth NHS Fdn Trust, Frimley Pk Hosp, Camberley, Surrey, England
[5] Univ Fed Minas Gerais, Programa Posgrad Ciencia Saude Infectol & Med Tro, Belo Horizonte, MG, Brazil
关键词
Hepatitis B; Treatment eligibility; Guideline adherence; Antiviral therapy; Public health; Brazil; PRACTICE GUIDELINES; PRIMARY-CARE; MANAGEMENT; NATIONWIDE; STATEMENT; DISEASE; CANCER; FRANCE;
D O I
10.1590/0037-8682-0297-2021
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Background: Chronic hepatitis B (CHB) affects 257 million people worldwide. However, the proportion of patients eligible for treatment in the public health system has not been established. This study describes the clinical and laboratory profiles of untreated CHB patients and estimates the eligibility rate for antiviral therapy in accordance with the Brazilian Clinical Protocol and Therapeutic Guidelines. Methods: Records of 670 CHB patients were collected from May 2012 to September 2013 in Minas Gerais. Data from each patient were analyzed by hepatitis B virus (HBV) management. Results: 461 CHB patients were treatment-naive. Of these, 23 were HBeAg-positive, 352 were HBeAg-negative, and 14 were clinically diagnosed with cirrhosis. Periodic monitoring was performed in only three patients. However, 9.3% of untreated patients met the eligibility criteria for HBV treatment. Conclusions: Few CHB patients were active carriers and eligible candidates for antiviral therapy. This study revealed inadequate pretreatment conduct in the Brazilian public health system, emphasizing the need for regular laboratory follow-up for patients initially not eligible for treatment. Such information may indirectly subsidize the planning and improvement of actions and services related to optimal HBV management in the public sphere.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] A NOVEL AND SIMPLIFIED SCORE FOR DETERMINING TREATMENT ELIGIBILITY FOR PATIENTS WITH CHRONIC HEPATITIS B
    Geeratragool, Tanawat
    Tangkijvanich, Pisit
    Nimanong, Supot
    Chainuvati, Siwaporn
    Charatcharoenwitthaya, Phunchai
    Tanwandee, Tawesak
    Chotiyaputta, Watcharasak
    GASTROENTEROLOGY, 2023, 164 (06) : S1252 - S1253
  • [42] Clinical utility of the treatment eligibility score HEPSANET for chronic hepatitis B in Asia
    Wang, Jian
    Zhang, Zhiyi
    Zhu, Chuanwu
    Wu, Chao
    Huang, Rui
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 47
  • [43] Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus DNA to Assess Treatment Eligibility in Africa
    Shimakawa, Yusuke
    Ndow, Gibril
    Njie, Ramou
    Njai, Harr Freeya
    Takahashi, Kazuaki
    Akbar, Sheikh Mohammad Fazle
    Cohen, Damien
    Nayagam, Shevanthi
    Jeng, Adam
    Ceesay, Arnie
    Sanneh, Bakary
    Baldeh, Ignatius
    Imaizumi, Masayasu
    Moriyama, Kazushige
    Aoyagi, Katsumi
    D'Alessandro, Umberto
    Mishiro, Shunji
    Chemin, Isabelle
    Mendy, Maimuna
    Thursz, Mark R.
    Lemoine, Maud
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (07) : 1442 - 1452
  • [44] Predicting treatment eligibility for hepatitis B in low income regions: Can treatment scores without HBV DNA testing serve the purpose?
    McMahon, Brian J.
    Dusheiko, Geoffrey
    JOURNAL OF HEPATOLOGY, 2018, 69 (04) : 765 - 766
  • [45] Public health perspective on vaccine-preventable hepatitis: integrating hepatitis A and B vaccines into public health settings
    Hershey, JH
    Schowalter, L
    Bailey, SBC
    AMERICAN JOURNAL OF MEDICINE, 2005, 118 : 100 - 108
  • [46] Clinical investigations for SUS, the Brazilian public health system
    de Paula, Ana Patricia
    Giozza, Silvana Pereira
    Pereira, Michelle Zanon
    Boaventura, Patricia Souza
    Pacheco Santos, Leonor Maria
    Sachetti, Camile Giaretta
    Carranza Tamayo, Cesar Omar
    Guaragna Kowalski, Clarissa Campos
    Silva Elias, Flavia Tavares
    Serruya, Suzanne Jacob
    Guimaraes, Reinaldo
    SAO PAULO MEDICAL JOURNAL, 2012, 130 (03): : 179 - 186
  • [47] Historical Perspective of Homeopathy in the Brazilian Public Health System
    Fujino, Fernanda Maria Simoes da Costa
    Armond, Jane de Eston
    Ribeiro, Ana Paula
    de Souza, Patricia Colombo
    HOMEOPATHY, 2024,
  • [48] Financing of Pharmaceutical Services in Brazilian Public Health System
    Vieira, Fabiola Sulpino
    Zucchi, Paola
    SAUDE E SOCIEDADE, 2013, 22 (01): : 73 - 84
  • [49] COST OF OSTEOPOROTIC FRACTURES IN THE BRAZILIAN PUBLIC HEALTH SYSTEM
    Brandao, C. M. R.
    Machado, G. P. D. M.
    Drumond, H. A.
    Alemao, M. M.
    Acurcio, F. D. A.
    VALUE IN HEALTH, 2013, 16 (07) : A716 - A717
  • [50] Pharmaceutical assistance in the Brazilian public health care system
    Vieira, Fabiola Sulpino
    REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2010, 27 (02): : 149 - 156